Netarsudil

KOLOA, Hawaii — At Hawaiian Eye 2020, Tom Mitro, president and chief operating officer of Aerie Pharmaceuticals, discusses recent data, including results from the MOST phase 4 trial focusing on the use of Rhopressa (netarsudil ophthalmic solution 0.02%) in real-world experiences.

The FDA has approved a facility in Athlone, Ireland, for production of Rocklatan for the U.S. market, Aerie Pharmaceuticals announced in a press release.

The European Medicines Agency has accepted and will review the marketing authorization application for Roclanda, Aerie Pharmaceuticals announced in a press release.

A Japanese phase 2 clinical study of netarsudil ophthalmic solution showed a significant reduction in mean intraocular pressure compared with placebo, Aerie Pharmaceuticals announced in a press release.